Table 2 Pathways significantly enriched with differentially expressed genes (DEGs) in mesenteric lymph node (MLN), tracheal bronchial lymph node (TBLN), whole blood cell (WBC), and liver. Enriched pathways with a p-value < 0.05 are shown for each tissue and each pairwise comparison (Control vs. M. bovis (MB); control vs. Dual; MB vs. Dual). Rows marked with– indicate that there was non-significant enrichment in the tissue comparison
From: Host transcriptome response to Mycoplasma bovis and bovine viral diarrhea virus in bovine tissues
Comparison | Tissue | Pathway | Count | P-Value | DEGs |
|---|---|---|---|---|---|
Control vs. MB | WBC | - | - | - | - |
Control vs. MB | Liver | - | - | - | - |
Control vs. MB | TBLN | - | - | - | - |
Control vs. MB | MLN | bta00561:Glycerolipid metabolism | 3 | 1.67E-03 | DGAT2, LPL, PNPLA2 |
MB vs. Dual | WBC | bta05330:Allograft rejection | 2 | 2.64E-02 | LOC508646, BOLA-DOB |
| Â | Â | bta04940:Type I diabetes mellitus | 2 | 2.74E-02 | LOC508646, BOLA-DOB |
| Â | Â | bta05332:Graft-versus-host disease | 2 | 2.99E-02 | LOC508646, BOLA-DOB |
| Â | Â | bta05320:Autoimmune thyroid disease | 2 | 3.49E-02 | LOC508646, BOLA-DOB |
MB vs. Dual | Liver | bta01212:Fatty acid metabolism | 3 | 5.17E-03 | FASN, ACACA, FADS1 |
| Â | Â | bta03320:PPAR signaling pathway | 3 | 1.02E-02 | PLIN4, ANGPTL4, RXRG |
| Â | Â | bta00061:Fatty acid biosynthesis | 2 | 3.27E-02 | FASN, ACACA |
| Â | Â | bta05160:Hepatitis C | 3 | 4.35E-02 | OAS1X, OAS1Y, CLDN15 |
MB vs. Dual | TBLN | bta04061:Viral protein interaction with cytokine and cytokine receptor | 2 | 3.80E-02 | CCL14, CCL16 |
MB vs. Dual | MLN | - | - | - | - |
Control vs. Dual | WBC | - | - | - | - |
Control vs. Dual | Liver | bta03320:PPAR signaling pathway | 4 | 9.63E-04 | PLIN4, ANGPTL4, CPT1B, RXRG |
| Â | Â | bta00260:Glycine, serine and threonine metabolism | 3 | 5.61E-03 | BHMT, LOC112443696, GNMT |
| Â | Â | bta00270:Cysteine and methionine metabolism | 3 | 7.06E-03 | BHMT, LOC112443696, GNMT |
| Â | Â | bta01212:Fatty acid metabolism | 3 | 8.38E-03 | FASN, CPT1B, FADS1 |
| Â | Â | bta01100:Metabolic pathways | 9 | 2.89E-02 | MIOX, BHMT, LOC112443696, FASN, GDPD1, AK4, INMT, FADS1, GNMT |
| Â | Â | bta04152:AMPK signaling pathway | 3 | 3.51E-02 | SREBF1, FASN, CPT1B |
Control vs. Dual | TBLN | bta05143:African trypanosomiasis | 3 | 2.78E-03 | HBA, HBA1, IDO1 |
| Â | Â | bta05171:Coronavirus disease - COVID-19 | 4 | 1.93E-02 | OAS2, MX1, ISG15, C2 |
| Â | Â | bta05164:Influenza A | 3 | 4.97E-02 | OAS2, MX1, TNFSF10 |
Control vs. Dual | MLN | bta01212:Fatty acid metabolism | 3 | 2.28E-03 | SCD, FASN, ELOVL6 |
| Â | Â | bta00561:Glycerolipid metabolism | 3 | 3.02E-03 | DGAT2, GPAM, LPL |
| Â | Â | bta04152:AMPK signaling pathway | 3 | 1.00E-02 | SCD, LEP, FASN |
| Â | Â | bta00360:Phenylalanine metabolism | 2 | 2.43E-02 | GAT, LOC112441481 |
| Â | Â | bta01040:Biosynthesis of unsaturated fatty acids | 2 | 3.63E-02 | SCD, ELOVL6 |